Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs IV Lidocaine in Colorectal Surgery
NCT04005859Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupivacaine extended release liposome injection in postoperative pain (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Verbal Pain Scale and Postoperative Morphine Equivalents at 30 days. Started Feb 2018; status: completed.
02
Drugs
bupivacaine extended release liposome injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04005859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005859.